DTRMWXHS 12

Drug Profile

DTRMWXHS 12

Alternative Names: DTRM-12; DTRMWXHS12

Latest Information Update: 05 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Zhejiang DTRM Biopharma
  • Class Antineoplastics; Pyrazoles; Pyrimidines; Small molecules
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I B cell lymphoma; Chronic lymphocytic leukaemia

Most Recent Events

  • 09 Dec 2017 Efficacy and adverse events data from a phase I trial in B-cell lymphoma and Chronic lymphocytic leukaemia presented at the 59th Annual Meeting and Exposition of the American Society of Haematology (ASH-Hem)
  • 09 Dec 2017 Efficacy and adverse events data from a phase I trial in B-cell lymphoma presented at the 59th Annual Meeting and Exposition of the American Society of Haematology (ASH-Hem)
  • 09 Dec 2017 Pooled adverse events and pharmacokinetics data from two phase I trials in B-cell lymphoma and Chronic lymphocytic leukaemia presented at the 59th Annual Meeting and Exposition of the American Society of Haematology (ASH-Hem)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top